ICIs such as PD-1 inhibitors (pembrolizumab, nivolumab) and PD-L1 inhibitors (atezolizumab, durvalumab) block this interaction, reactivating immune-mediated tumor clearance [7,8]. The gene discussed is CD274; the disease is neoplasm.